Epizyme to Report First Quarter 2016 Financial Results and Provide Corporate Update on May 9, 2016 and to Participate in Upcoming May Conferences

CAMBRIDGE, Mass.--()--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, announced today that management will host a conference call and live audio webcast on Monday, May 9, 2016, at 8:00 a.m. Eastern Time to report first quarter 2016 financial results and provide a corporate update. In addition, the company will be participating in two investor conferences in the month of May, Bank of America Merrill Lynch 2016 Health Care Conference and the UBS Global Health Care Conference.

First Quarter 2016 Earnings Call and Webcast

The call and live webcast will take place on May 9, 2016 at 8:00 a.m. Eastern Time. To participate in the conference call, please dial (877) 497-1428 (domestic) or (929) 387-3949 (international) and refer to conference ID 90135413. The live webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.epizyme.com.

May Investor Conference Participation

  • Bank of America Merrill Lynch 2016 Health Care Conference
    Presentation will be webcasted and take place on May 11, 2016 at 4:20 p.m. Pacific Time.
    A replay of the webcast can be accessed at the investor section of http://www.epizyme.com
  • UBS Global Health Care Conference
    Presentation will be webcasted and take place on May 23, 2106 at 11:00 a.m. Eastern Time.
    A replay of the webcast can be accessed at the investor section of http://www.epizyme.com

About Epizyme, Inc.

Epizyme, Inc. is a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of chromatin modifying proteins (CMPs), such as histone methyltransferases or HMTs. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients.

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Contacts

Investors:
Rebecca Cohen, 617-401-0722
Epizyme, Inc.
Investor Relations and Corporate Communications
rcohen@epizyme.com
Media:
Michael Lampe, 484-575-5040
Scient Public Relations
michael@scientpr.com

Contacts

Investors:
Rebecca Cohen, 617-401-0722
Epizyme, Inc.
Investor Relations and Corporate Communications
rcohen@epizyme.com
Media:
Michael Lampe, 484-575-5040
Scient Public Relations
michael@scientpr.com